Compositions and methods for treating cancer

Patent metadata

Field	Value
Publication number	US-2016130659-A1
Application number	US-201414894705-A
Country	US
Kind code	A1
Filing date	Jun 3, 2014
Priority date	Jun 5, 2013
Publication date	May 12, 2016
Grant date	—

Abstract

The instant invention relates to methods for the treatment of B-cell lymphomas and leukemia by administering a SYK inhibitor. In another embodiment, the invention relates to a method for treating a patient diagnosed with a B-cell lymphoma or leukemia, comprising administering a SYK inhibitor, wherein the B-cells of said patient to be treated are characterized by elevated expression levels of CD86.

First claim

1 . A method for treating a patient diagnosed with a B-cell lymphoma or leukemia with a SYK inhibitor comprising the steps of:
(a) selecting a patient for treatment with a SYK inhibitor, wherein a malignant B-cell containing biological sample of the patient has elevated CD86 expression; and (b) administering a therapeutically effective amount of the SYK inhibitor to the selected patient.

2 . The method of claim 1 , comprising the steps of:
(a) measuring the expression level of CD86 in the biological sample from said patient; (b) determining whether the CD86 expression level in said patient sample is above or below the level of a control sample; (c) selecting said patient for treatment with a SYK inhibitor, wherein the level of the CD86 expression from said patient sample is at or above that of the control sample; and (d) administering a therapeutically effective amount of the SYK inhibitor to the selected patient.

3 . The method according to claim 1 , wherein said control sample is a malignant B-cell containing biological sample obtained from one or more subjects diagnosed with B-cell lymphoma or leukemia, but do not respond to treatment with a SYK inhibitor.

4 . A method for treating a patient diagnosed with a B-cell lymphoma or leukemia, in which a malignant B-cell containing biological sample of the patient has elevated expression levels of CD86, comprising the step of: administering a therapeutically effective amount of a SYK inhibitor to the patient.

5 . The method according to claim 4 , wherein the elevated expression levels of CD86 is in comparison to a reference derived from the CD86 expression level in a malignant B-cell containing biological sample of one or more subjects diagnosed with B-cell lymphoma or leukemia but do not respond to treatment with a SYK inhibitor.

6 . The method according to claim 4 , wherein the mRNA or protein expression level of CD86 is measured.

7 . The method according to claim 4 , wherein said B-cell lymphoma or leukemia is selected from the group consisting of acute leukemia, chronic lymphatic leukemia, chronic myelocytic leukemia, and non-Hodgkin's lymphoma.

8 . The method according to claim 4 , wherein the patient is diagnosed with diffuse large B-cell lymphoma.

9 . A method for treating a B-cell lymphoma or leukemia patient, comprising the step of administering a therapeutically effective amount of a SYK inhibitor to the patient, wherein a malignant B-cell containing biological sample of said patient is characterized by elevated expression of CD86.

10 . The method according to claim 9 , wherein the elevated expression levels of CD86 is in comparison to a reference derived from the CD86 expression level in a malignant B-cell containing biological sample of one or more subjects diagnosed with B-cell lymphoma or leukemia but do not respond to treatment with a SYK inhibitor.

11 . The method according to claim 9 , wherein the mRNA or protein expression level of CD86 is measured.

12 . The method according to claim 9 , wherein said B-cell lymphoma or leukemia is selected from the group consisting of acute leukemia, chronic lymphatic leukemia, chronic myelocytic leukemia, and non-Hodgkin's lymphoma.

13 . The method according to claim 9 , wherein the patient is diagnosed with diffuse large B-cell lymphoma.

14 . A kit to identify a B-cell lymphoma or leukemia patient sensitive to treatment with a SYK inhibitor comprising a detection agent capable of detecting the expression product of CD86 in a biological test sample.

Assignees

• Merck Sharp & Dohme

Inventors

• Macisaac Kenzie
• Kraus Manfred
• Strack Peter Richard
• Nagashima Kumiko
• Ellis John Michael

Classifications

• G01N33/57505

  of the blood, e.g. leukaemia · CPC title

• G01N33/57426

  Physics · mapped topic

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title